Added to YB: 2026-02-16
Pitch date: 2025-12-03
CYTK [bullish]
Cytokinetics, Incorporated
+1.37%
current return
Author Info
No bio for this author
Company Info
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Market Cap
$8.1B
Pitch Price
$64.06
Price Target
200.00 (+208%)
Dividend
N/A
EV/EBITDA
-14.41
P/E
-10.08
EV/Sales
98.53
Sector
Biotechnology
Category
growth
Cytokinetics, Incorporated - $CYTK
CYTK: PDUFA 12/26/25 for aficamten in oHCM. Next-in-class cardiac myosin inhibitor vs BMS's Camzyos ($693M 2024 sales). Superior profile: fewer side effects, less drug interactions, faster titration. Ph3 SEQUOIA & MAPLE trials beat placebo & metoprolol. $3-4B peak sales est in $2.5B+ HCM market. $7.7B mcap. Catalysts: approval, nHCM data early '26, sales ramp '26-'27, potential M&A. 3x upside 12-36mo
Read full article (5 min)